[12-04]Understanding interindividual variations in pharmacotherapy: PharmacoGenetics to PharmacoEpigenetics

报告题目：Understanding interindividual variations in pharmacotherapy: PharmacoGenetics to PharmacoEpigenetics

报  告 人：喻爱明（美国加州大学戴维斯分校生物化学与分子医学终身教授）

报告时间：2013年12月4日（周三）10:30

报告地点：独墅湖校区二期云轩楼2301室

报告人简介：

Ai-Ming Yu, Ph.D.

Associate Professor, Department of Biochemistry & Molecular Medicine

Director of The PK/PD Bioanalytical Laboratory

Member of Comprehensive Cancer Center

University of California, Davis

2700 Stockton Blvd., Suite 2132

Sacramento, CA 95817

Phone: (916) 734-1566

Fax: (916) 734-4418

http://www.ucdmc.ucdavis.edu/biochem/faculty/Yu_index.html

Dr. Yu obtained his Ph.D. at Nankai University in 1998. He then worked as a postdoc scholar at University of Washington and West Virginia University, and a research fellow at the National Institutes of Health. He became an Assistant Professor at SUNY-Buffalo in 2004, and was promoted to Associated Professor with tenure in 2010. He moved to his current position at UC Davis in 2013.

Prof. Yu’s research interests include pharmacoepigenetics, pharmacogenetics, and cancer therapy. The ultimate goal of his research is to define the mechanistic functions of noncoding RNAs in the control of cellular processes such as drug disposition and tumor progression, and to develop novel noncoding RNA-based therapies. Currently, efforts in his laboratory are directed to the investigation of (a) the roles of noncoding RNAs in the regulation of cytochrome P450 drug-metabolizing enzymes, ATP-binding cassette transporters and oncogenes, and (b) noncoding RNA signaling and mechanisms in tumor development as well as noncoding RNA-based cancer therapeutics.

报告摘要:

Understanding interindividual variability in pharmacokinetics and pharmacodynamics is critical for drug development and pharmacotherapy. Drug absorption, distribution, metabolism and excretion (ADME) processes are mediated by drug-metabolizing enzymes and transporters expressed in various tissues, which may determine the pharmacokinetic property of the drug. Therefore, understanding the regulation of ADME gene expression is critical for the prediction of consequent pharmacological and toxicological effects. Genetic variation has been known as an important factor underlying variable pharmacokinetics. There is also increasing evidence supporting the roles of epigenetic factors including DNA methylation proteins, histone-modifying enzymes, and noncoding RNAs in drug metabolism and pharmacokinetics through transcriptional or post-transcriptional regulation of ADME genes. This talk will present our findings on CYP2D6 drug-metabolizing enzyme and noncoding microRNAs to illustrate the importance of pharmacogenetics and pharmacoepigenetics.